Lucis, a Paris-based preventive health startup launched in 2025, announced on December 16, 2025 the closing of a €7.2 million ($8.5M) seed round. The round was led by General Catalyst, with participation from Y Combinator, Kima Ventures, Motier Ventures, Circle.Co and North South Ventures. The company positions itself as the European equivalent of US-based Function Health.
A seed round to build out the European market
The round, reported by EU-Startups, funds a pan-European expansion already underway. Lucis already operates in France, the United Kingdom, Ireland and Portugal through a network of partner medical laboratories.
Three priorities have been announced:
- Geographic expansion: covering Germany, Spain and Italy over the next 18 months.
- Expanded clinical offering with new biomarkers and the likely integration of medical imaging.
- Hiring across engineering, medical and operations functions.
The product: 180 biomarkers analyzed by AI, supervised by physicians
The service is built around a simple journey for members:
- Subscribing to an annual plan.
- Blood draw at a certified medical laboratory (Cerba, Synlab, or Eurofins network, depending on the country).
- Analysis of more than 180 biomarkers covering cardiovascular, metabolic, hormonal, renal, hepatic, and inflammatory markers.
- Results delivered in the Lucis app, with AI analysis and physician review.
- A personalized action plan covering nutrition, exercise, sleep, supplements, and mental health.
- Longitudinal tracking of changes across regular check-ups.
The technology angle combines AI for large-scale analysis of results with a regulated medical framework. According to TechFundingNews, the company claims short turnaround times and a fully digital onboarding process.
Market: a preventive health segment that's booming
Data from Stratistics MRC values the global longevity clinic and preventive health market at $23.4 billion in 2025, with a projection of $46.6 billion by 2032 (CAGR 10.3%). The broader preventive health technology segment is expected to exceed $920 billion by 2034, according to Precedence Research.
Several factors are driving this growth:
- The consumerization of diagnostics, with subscription models of €500–€1,500/year that make check-ups once reserved for luxury private medicine widely accessible.
- Pressure on public healthcare systems, which struggle to offer structured preventive care.
- Growing interest in longevity and 4P medicine (preventive, predictive, personalized, participative).
The American ecosystem has paved the way. Function Health offers a $499 annual subscription with 100+ biomarkers, and in 2025 acquired the whole-body MRI platform Ezra. Lucis applies this playbook to the European context, where the fragmentation of healthcare systems creates both a challenge (multiple regulations) and an opportunity (local players have yet to consolidate the offering).
Competition: three categories of players
- US subscription models: Function Health, Hone Health, LifeForce, Fountain Life. Very well-funded, but with little presence in Europe.
- European longevity clinics: Numan (UK), Health Mate, and a host of private clinics where the experience remains expensive and fragmented.
- Traditional diagnostic players: Synlab, Cerba, or Eurofins, which do not operate the software layer and remain dependent on medical prescriptions.
Lucis's advantage lies in its European DTC subscription positioning, still relatively uncontested, and in its vertical lab-to-app integration.
Why General Catalyst is investing
General Catalyst is one of the most active funds worldwide in the healthcare segment. Its backing of Lucis fits into a broader thesis: transforming European primary care through consumer-tech platforms that combine diagnostics, AI, and precision medicine. The presence of Y Combinator brings US brand equity and network — decisive if the company is targeting international expansion beyond Europe.
For healthtech founders structuring their growth strategy, this investor mix (global healthcare fund + US accelerator + European consumer funds) has become the dominant pattern for pan-European ambitions — it combines media reach, capital, and operational know-how.
Execution risks
Three areas to watch:
- Regulatory compliance: every European country has its own rules on prescribing and medical interpretation, particularly restrictive in Germany and Italy.
- Customer acquisition cost: subscription-based preventive health is still a product that requires long education cycles. Lucis needs to prove a quality CAC payback.
- Retention at 12 months: the risk of churn after the first check-up is documented among US players and calls for a stronger engagement layer.
What this means for health/AI players in Europe
Lucis confirms that AI applied to healthcare is not limited to the imaging tools or clinical diagnostics reserved for hospitals. A consumer-grade software layer, built on an ecosystem of existing labs, can create an entirely new category. The timing is right: growing public awareness of prevention is meeting a wave of AI capable of reading and synthesizing complex health assessments into actionable insights.
The CB Insights report on longevity tech lists more than $9.3 billion invested in longevity biotechs and preventive health between 2023 and 2025 — a volume that validates the maturity of the segment and the seriousness of the positioning Lucis has chosen. The European window of opportunity remains open as long as no player has yet consolidated demand, which justifies the urgency of the announced geographic expansion.
FAQ
How much has Lucis raised?
Lucis closed a €7.2 million seed round ($8.5M) announced on December 16, 2025, led by General Catalyst with Y Combinator, Kima Ventures, Motier Ventures, Circle.Co and North South Ventures.
What exactly does Lucis do?
The company offers an annual subscription to a preventive health service. Members get laboratory blood tests (180+ biomarkers), Lucis interprets the results with AI backed by medical validation, and delivers a personalized action plan through the app.
In which countries does Lucis operate?
The service is live in France, the United Kingdom, Ireland and Portugal. Expansion into Germany, Spain and Italy is planned within 18 months.
Who are the direct competitors in Europe?
No consolidated pan-European player exists to date. Lucis competes with Function Health (US-based, with limited presence in Europe), Numan in the United Kingdom, and a range of private longevity clinics.
How big is the preventive health market?
According to Stratistics MRC, the longevity clinics and preventive health segment is worth $23.4 billion in 2025 and is expected to reach $46.6 billion by 2032, a CAGR of 10.3%.